{"entity":{"id":"innovent","kind":"company","name":"Innovent Biologics","aka":["信达生物","Innovent Biologics (Suzhou)","Innovent Biopharmaceutical Technology (Hangzhou)","Innovent Biologics"],"tldr":"Innovent makes sintilimab, China's best-selling PD-1 antibody, and has become a source of next-generation assets for Roche and Takeda.","summary":"Founded by Michael Yu in Suzhou BioBay; sintilimab (Tyvyt) approved 2018 and now in six indications, four biosimilars (bevacizumab, rituximab, adalimumab, trastuzumab), fulzerasib (with GenFleet), equecabtagene autoleucel (with IASO), and the Claudin 18.2 ADC IBI343. Out-licensing: the DLL3 ADC IBI3009 to Roche (January 2025) and the PD-1/IL-2 alpha-bias bispecific IBI363 plus IBI343 to Takeda (October 2025, $1.2 billion upfront, up to $11.4 billion). Also the GLP-1 mazdutide outside oncology. Lilly co-markets Tyvyt in China.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Innovent_Biologics","links":[{"label":"Official website","url":"https://www.innoventbio.com/"},{"label":"Innovent and Takeda global partnership (October 2025)","url":"https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=524"}],"tags":["china"],"related":[],"cancers":[],"sections":["immunotherapy","adcs","cell-therapy"],"technologies":[],"targets":[],"drugs":["sintilimab","fulzerasib","equecabtagene-autoleucel","ibi354","ibi343","ibi310","ibi363","taletrectinib"],"companies":["eli-lilly","roche-genentech","takeda"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05923008","nct05890742","nct05636215","nct06083207","nct06974812","nct05116462","nct07722494","nct06797297","nct06081920","nct07483554","nct06281678","nct07122687"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.innoventbio.com/","ticker":"1801.HK","founded":2011,"investors":[],"funding":[]},"route":"/companies/innovent/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/"},{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/"},{"id":"ibi310","kind":"drug","name":"IBI310","route":"/drugs/ibi310/"},{"id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/"},{"id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/"},{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"},{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"},{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/"},{"id":"iaso-bio","kind":"company","name":"IASO Biotherapeutics","route":"/companies/iaso-bio/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}],"trial":[{"id":"nct05923008","kind":"trial","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05923008/"},{"id":"nct06982924","kind":"trial","name":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","route":"/trials/nct06982924/"},{"id":"nct05890742","kind":"trial","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","route":"/trials/nct05890742/"},{"id":"nct05636215","kind":"trial","name":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct05636215/"},{"id":"g-hope-002","kind":"trial","name":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","route":"/trials/g-hope-002/"},{"id":"nct06083207","kind":"trial","name":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06083207/"},{"id":"nct06081920","kind":"trial","name":"A Study of IBI363 in Subjects With Advanced Melanoma","route":"/trials/nct06081920/"},{"id":"nct06281678","kind":"trial","name":"A Study of IBI363 in Subjects with Advanced Solid Malignancies","route":"/trials/nct06281678/"},{"id":"nct07490262","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment","route":"/trials/nct07490262/"},{"id":"nct06797297","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat","route":"/trials/nct06797297/"},{"id":"continuum","kind":"trial","name":"CONTINUUM","route":"/trials/continuum/"},{"id":"nct07492342","kind":"trial","name":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","route":"/trials/nct07492342/"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/"},{"id":"nct06974812","kind":"trial","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06974812/"},{"id":"nct07483554","kind":"trial","name":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","route":"/trials/nct07483554/"},{"id":"nct07198841","kind":"trial","name":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07198841/"},{"id":"nct07377643","kind":"trial","name":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","route":"/trials/nct07377643/"},{"id":"nct07402070","kind":"trial","name":"IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer","route":"/trials/nct07402070/"},{"id":"nct07722494","kind":"trial","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","route":"/trials/nct07722494/"},{"id":"nct07122687","kind":"trial","name":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small","route":"/trials/nct07122687/"},{"id":"nct05116462","kind":"trial","name":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","route":"/trials/nct05116462/"},{"id":"orient-11","kind":"trial","name":"ORIENT-11","route":"/trials/orient-11/"},{"id":"orient-16","kind":"trial","name":"ORIENT-16","route":"/trials/orient-16/"},{"id":"orient-32","kind":"trial","name":"ORIENT-32","route":"/trials/orient-32/"},{"id":"nct06121505","kind":"trial","name":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","route":"/trials/nct06121505/"},{"id":"nct07535632","kind":"trial","name":"SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer","route":"/trials/nct07535632/"},{"id":"nct06834672","kind":"trial","name":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","route":"/trials/nct06834672/"}],"person":[{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","route":"/people/yu-michael/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}],"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}]}}